Precipio (NASDAQ: PRPO) reported a quarterly loss of $(0.12) per share for the second quarter, marking a significant shift from the $0.05 per share profit recorded in the corresponding period last year. This represents a 340% decline in earnings per share year-over-year.

Despite the erosion in bottom-line profitability, the company demonstrated robust top-line expansion. Sales for the quarter reached $7.021 million, up 24.18% from $5.654 million in the same period last year.

What the Numbers Show

The divergence between revenue growth and earnings performance highlights a compression in profitability margins. While Precipio successfully expanded its revenue base by nearly a quarter, this growth did not translate into proportional earnings. The shift from a positive EPS of $0.05 to a negative $(0.12) suggests that operating costs or expenses increased at a faster rate than revenue during the period.

The data indicates that while demand or volume drivers supported higher sales figures, the company faced margin pressure that resulted in a net loss for the quarter.

Specialty cancer diagnostics company Precipio Inc. (NASDAQ: PRPO) will host its Q2-2026 shareholder update call on August 17, 2026, at 5:00 PM ET. The conference call aims to provide investors with insights into the company’s operational progress and strategic direction. CEO Ilan Danieli stated that the team continues to make solid progress in adding customers and expanding its pipeline, which will be reflected in the upcoming numbers. This update serves as a key communication channel for stakeholders seeking clarity on the company’s performance trajectory.

Call Agenda and Participation

The agenda for the August 17 call includes remarks on Precipio’s current core businesses followed by a moderated live Q&A session. Management intends to address investor questions regarding performance, strategy, and growth initiatives. Participants wishing to ask questions during the live call must log into the Q&A system and identify themselves along with their organization or status as individual investors.

Investors may also submit questions in advance by emailing investors@precipiodx.com . Management indicated it would do its best to address these pre-submitted queries during the broadcast. The conference call can be accessed by dialing 646.307.1865 and requesting the Precipio Inc. conference call.

Access and Replay Details

A replay of the call will be available approximately 24 hours after the live event. Listeners can access the replay via the Investors page on Precipio’s website at https://www.precipiodx.com/investors/ . The company encourages regular review of its website and social media channels, including X (@PrecipioDx) and LinkedIn, as material information may be posted there.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address cancer misdiagnoses by developing diagnostic products and services that deliver higher accuracy and improved laboratory workflow. These solutions aim to improve patient outcomes and reduce healthcare expenses. Precipio develops innovative technologies in its laboratory, where it designs, tests, validates, and uses products clinically before commercializing them for the global laboratory community.